In mice, both CB1 agonists and antagonists enhanced antidepressant effects of tianeptine, while CB1 and CB2 antagonists augmented agomelatine, all without changing brain drug levels.
Psychopharmacologists, endocannabinoid researchers, and clinicians interested in antidepressant augmentation strategies.
Both CB1 activation and blockade enhanced atypical antidepressant effects in mice
What the researchers found
In mouse forced swim and tail suspension tests, sub-effective doses of CB receptor ligands enhanced antidepressant activity: oleamide (CB1 agonist) potentiated tianeptine; AM251 (CB1 antagonist) enhanced both tianeptine and agomelatine; AM630 (CB2 inverse agonist) augmented both drugs in the forced swim test only. None of the combinations affected brain levels of the antidepressants, indicating pharmacodynamic rather than pharmacokinetic interaction.
Why it matters
Atypical antidepressants like agomelatine and tianeptine work through unique mechanisms (melatonin and opioid pathways). Finding that cannabinoid compounds enhance their effects without changing brain concentrations suggests a true synergistic interaction worth exploring.
The numbers in context
Oleamide 5 mg/kg + tianeptine 15 mg/kg: significant anti-immobility in FST and TST; AM251 0.25 mg/kg enhanced both drugs; AM630 0.25 mg/kg enhanced both in FST only; no brain level changes.
How the study worked
Mouse behavioral studies using forced swim test (FST) and tail suspension test (TST) to assess antidepressant-like effects of cannabinoid receptor ligands combined with atypical antidepressants (agomelatine, tianeptine). HPLC measured brain drug levels.
What this study cannot tell us
Animal model only (mouse behavioral tests have limited translational value); sub-effective doses may not translate to clinical use; forced swim test validity debated; only two atypical antidepressants tested; acute dosing only.
How to read the evidence
Preliminary: animal behavioral study with limited translational certainty.
When this study was published
Published 2020.
The bigger picture
That both CB1 activation (oleamide) and CB1 blockade (AM251) enhanced antidepressant effects seems contradictory but may reflect dose-dependent or receptor-population-specific effects. This complexity suggests the endocannabinoid system modulates mood through multiple pathways.
Questions still open
- How can both CB1 activation and blockade enhance antidepressant effects? Would cannabinoid augmentation reduce the effective dose of antidepressants needed in humans?
Common questions
Can cannabinoids improve antidepressant effectiveness?
Would this work in humans?
Read the original research
Influence of the CB1 and CB2 cannabinoid receptor ligands on the activity of atypical antidepressant drugs in the behavioural tests in mice.
Pharmacology, biochemistry, and behavior, 188, 172833
Citation
Poleszak, Ewa; Wośko, Sylwia; Sławińska, Karolina; Wyska, Elżbieta; Szopa, Aleksandra; Świąder, Katarzyna; Wróbel, Andrzej; Doboszewska, Urszula; Wlaź, Piotr; Wlaź, Aleksandra; Serefko, Anna. (2020). Influence of the CB1 and CB2 cannabinoid receptor ligands on the activity of atypical antidepressant drugs in the behavioural tests in mice.. Pharmacology, biochemistry, and behavior, 188, 172833. https://doi.org/10.1016/j.pbb.2019.172833
Explore the wider topic
- LGBTQ+ and Cannabis: Higher Use Rates and Recovery
- Cannabis-Induced Psychosis: What It Is, Who's at Risk, and What to Do
- BetterHelp, Cerebral, and Online Therapy: Honest Review
- Quitting Weed with ADHD: Why It Is Harder and What Actually Helps
- Quitting Weed with Depression: What You Need to Know
- Quitting Weed with PTSD: A Practical Guide
- Self-Medicating with Weed: Why It Works Until It Doesn't
- Weed and OCD: Self-Medicating Intrusive Thoughts
- Weed and PTSD: What the Research Actually Shows
- Weed and Childhood Trauma: ACEs, Self-Medication, and the Path to Real Healing
- Weed and Suicidal Thoughts: What You Need to Know
- THC and SSRIs: What Happens When You Mix Cannabis and Antidepressants